Actively Recruiting
Phase III Study of LM-350 to Evaluate Safety, Tolerability, and Preliminary Effectiveness in Adults With Advanced Solid Tumors
Led by LaNova Medicines Limited · Updated on 2026-01-26
80
Participants Needed
4
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating LM-350, an experimental drug, for safety, tolerability, and preliminary anti-tumor activity in patients with advanced solid tumors. The study is a Phase III clinical trial designed to find the maximum tolerated or optimal biological dose and explore how biomarkers relate to the drugs anti-tumor effects. This trial is sponsored by LaNova Medicines Limited and includes patients who have failed or cannot tolerate standard treatments. Participants will receive LM-350 by intravenous drip every three weeks during the study. The trial consists of a Phase I dose escalation to determine safe dosage levels, followed by a Phase II dose expansion to assess early anti-tumor activity. Treatment and monitoring continue over extended periods to evaluate the drugs effects and safety. During the study, participants will undergo regular assessments including physical exams, vital signs, blood and urine tests, ECGs, echocardiography, and tumor biomarker analyses. Researchers will track side effects, tumor response, pharmacokinetics, and immune response over up to 130 weeks. Safety monitoring includes checking for adverse events, heart function, and laboratory parameters to ensure participant well-being throughout the trial.
CONDITIONS
Brief Title
A Study of LM-350 in Subjects With Advanced Solid Tumours
Research Team
A
Alex Yuan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here